Concepedia

Lnc‐SOX6‐1 upregulation correlates with poor risk stratification and worse treatment outcomes, and promotes cell proliferation while inhibits apoptosis in pediatric acute myeloid leukemia

Xianmin Guan, Xianhao Wen, Jianwen Xiao, Xizhou An, Jie Yu, Yuxia Guo

International Journal of Laboratory Hematology · 2019 · 12 citations · 14 references

DOI

Abstract

Lnc-SOX6-1 is highly expressed and correlates with worse risk stratification and poor treatment outcomes, and promotes cell proliferation while represses apoptosis in pediatric AML.

References

14

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

Jeffrey E. Rubnitz, Hiroto Inaba, Gary V. Dahl et al. · The Lancet Oncology · 2010 · 571 citations

, , +8

Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group

Beverly J. Lange, Franklin O. Smith, James H. Feusner et al. · Blood · 2007 · 272 citations · Full text

Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial

Brenda Gibson, David Webb, Andrew Howman et al. · British Journal of Haematology · 2011 · 204 citations

Response-Guided Induction Therapy in Pediatric Acute Myeloid Leukemia With Excellent Remission Rate

Jonas Abrahamsson, Erik Forestier, Jesper Heldrup et al. · Journal of Clinical Oncology · 2010 · 192 citations

AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia

Todd M. Cooper, Janet Franklin, Robert B. Gerbing et al. · Cancer · 2011 · 192 citations · Full text